Faquetti Maria Luisa, Frey Géraldine, Stämpfli Dominik, Weiler Stefan, Burden Andrea M
Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, Switzerland.
Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland.
Br J Clin Pharmacol. 2024 Jun;90(6):1376-1394. doi: 10.1111/bcp.16018. Epub 2024 Feb 26.
The aim of this study was to estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting their first noninsulin antidiabetic treatment (NIAD) using two explicit process measures of the appropriateness of prescribing in UK primary care, stratified by age and polypharmacy status.
A descriptive cohort study between 2016 and 2019 was conducted to assess PIPs in patients aged ≥45 years at the start of their first NIAD, stratified by age and polypharmacy status. The American Geriatrics Society Beers criteria 2015 was used for older (≥65 years) patients and the Prescribing Optimally in Middle-age People's Treatments criteria was used for middle-aged (45-64 years) patients. Prevalence of overall PIPs and individual PIPs criteria was reported using the IQVIA Medical Research Data incorporating THIN, a Cegedim Database of anonymized electronic health records in the UK.
Among 28 604 patients initiating NIADs, 18 494 (64.7%) received polypharmacy. In older and middle-aged patients with polypharmacy, 39.6% and 22.7%, respectively, received ≥1 PIP. At the individual PIP level, long-term proton pump inhibitors (PPI) use was the most frequent PIP among older adults, and strong opioid without laxatives was the most frequent PIP in middle-aged patients with polypharmacy (11.1% and 4.1%, respectively).
This study revealed that patients starting NIAD treatment receiving polypharmacy have the potential for pharmacotherapy optimization.
本研究旨在使用英国初级医疗中两种明确的处方适宜性流程指标,对开始首次非胰岛素抗糖尿病治疗(NIAD)的患者中潜在不适当处方(PIP)的患病率进行估计,并按年龄和多重用药状态进行分层。
开展了一项2016年至2019年间的描述性队列研究,以评估首次开始NIAD治疗时年龄≥45岁的患者中的PIP,按年龄和多重用药状态进行分层。2015年美国老年医学会Beers标准用于老年(≥65岁)患者,中年(45 - 64岁)患者则使用中年人群治疗中优化处方标准。使用包含THIN的IQVIA医学研究数据报告总体PIP和个体PIP标准的患病率,THIN是英国一个匿名电子健康记录的Cegedim数据库。
在28604例开始NIAD治疗的患者中,18494例(64.7%)接受了多重用药。在有多重用药情况的老年和中年患者中,分别有39.6%和22.7%接受了≥1种PIP。在个体PIP层面,长期使用质子泵抑制剂(PPI)是老年患者中最常见的PIP,而在有多重用药情况的中年患者中,无缓泻剂的强效阿片类药物是最常见的PIP(分别为11.1%和4.1%)。
本研究表明,开始接受NIAD治疗且接受多重用药的患者有进行药物治疗优化的潜力。